Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Hold” by the four analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $16.67.

Several research firms recently commented on ATRA. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $25.00 to $18.00 in a report on Friday, August 16th. Finally, Canaccord Genuity Group boosted their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th.

Institutional Trading of Atara Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics during the second quarter worth about $53,000. Geode Capital Management LLC raised its position in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares during the last quarter. State Street Corp grew its stake in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. Finally, FMR LLC raised its holdings in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Down 6.0 %

Shares of NASDAQ ATRA opened at $12.00 on Monday. The company has a market capitalization of $69.12 million, a PE ratio of -0.47 and a beta of 0.50. The firm has a fifty day simple moving average of $9.00 and a 200 day simple moving average of $10.18. Atara Biotherapeutics has a twelve month low of $6.50 and a twelve month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the business posted ($16.50) earnings per share. As a group, equities analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.